Skip to content
‹ Back to IndustriesHealthcare

Sustaining 2017’s MIPS Success Through 2019

The performance of physicians is measured in several ways, and now they are being rewarded for tangible benchmarks. The Centers for Medicare and Medicaid Services (CMS) is required by law to implement a quality payment incentive program, referred to as the Quality Payment Program (QPP), which rewards practice value and outcomes. As such, the Merit-based Incentive…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.

Start free

The performance of physicians is measured in several ways, and now they are being rewarded for tangible benchmarks.

The Centers for Medicare and Medicaid Services (CMS) is required by law to implement a quality payment incentive program, referred to as the Quality Payment Program (QPP), which rewards practice value and outcomes. As such, the Merit-based Incentive Payment System (MIPS) was designed to tie payments to quality and cost-efficient care, drive improvement in care processes and health outcomes, increase the use of healthcare information and reduce the cost of care. Program participants must report data collected during the calendar year, beginning January 1st and ending December 31st, with data graded in several areas. Data collected in one year must be reported by March 31st of the following year to be eligible for a payment increase and avoid a payment reduction for the next year.

Success of MIPS in 2017

Recently, the CMS published the Quality Payment Program Reporting Experiencereport. Exceeding CMS’s goal of 90% physician participation, the results found that 95% of 1,057,824 eligible clinicians avoided a negative payment adjustment through the 2017 MIPS, with 93% earning a positive payment adjustment. This data is overwhelmingly promising considering 2017 was the first year CMS ran the QPP, making reporting in MIPS’ inaugural performance year an unequivocal successful.

Why You Need to Report

It is essential that physicians continue to participate and report through 2019, as well as each year going forward. Making MIPS reporting habitual will benefit eligible physicians because as the years go by, both the incentives and penalties related to the process will only increase. The highest payment adjustment applied to participants in the 2019 payment year is 1.88%, according to Revcycle Intelligence. Although reporting may become increasingly difficult going forward, it is crucial that as many eligible participants report through MIPS in order to receive a more substantial payment adjustment. Further, reporting above the recommended threshold will pay immense dividends, not only this year but well into the future. CMS stated that in 2017, most participants did, in fact, report more than the minimum—a very positive sign.

How MIPS Works

To better understand how MIPS scores are calculated, the CMS grades physicians on four core performance categories:

  • Quality: This is measured by the quality of care provided to patients by the physician. He or she picks the six measures of performance that best fit their specific practice.
  • Promoting Interoperability: This area assesses the amount of comprehensive and relevant information shared by one clinic with another, including test results and/or summaries.
  • Improvement Activities: This category measures enhancements made to the type of care provided, internal processes or other internal operations throughout a calendar year that keeps a practice current with and or surpasses industry standards and innovations. Much like the quality score, clinics can choose the appropriate activities to report.
  • Cost: The total cost of a typical clinic visit is gauged here and will be calculated based on Medicare claims registered at each specific practice.

Physicians that meaningfully participated in the program, began reporting early in the year and remained motivated in reporting throughout the entire calendar year experienced measurable success

ChartLogic, Invested in Physician Success

At ChartLogic, our mission is to positively impact patient care by delivering award-winning healthcare IT solutions to providers of every size and budget. We offer an ambulatory EHR suite with access to practice management and revenue cycle management services with a system built on understanding workflow and preferences intuitively, facilitating faster note taking and much more. For 25 years, we have been driven by the desire to improve patient care, office efficiency, and profitability for the physician practice. We stay current with technology and legislation that affect our client practices, helping to educate them while encouraging participation in programs that can affect their success. ChartLogic is the physician practice’s true health care partner and we can help your practice become MIPS ready. To learn more about ChartLogic’s vast suite of products and services, you can view our solutions here.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0. No credit card. Company confirmation required.

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512